6L9 Stock Overview
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ViewRay, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.025 |
| 52 Week High | US$4.60 |
| 52 Week Low | US$0.0005 |
| Beta | 0.76 |
| 1 Month Change | 0% |
| 3 Month Change | 284.62% |
| 1 Year Change | -99.39% |
| 3 Year Change | -99.04% |
| 5 Year Change | -99.68% |
| Change since IPO | -99.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6L9 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | -0.8% |
| 1Y | -99.4% | -3.3% | 1.0% |
Return vs Industry: 6L9 underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: 6L9 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 6L9 volatility | |
|---|---|
| 6L9 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6L9's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 6L9's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 295 | Paul Ziegler | www.viewray.com |
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors.
ViewRay, Inc. Fundamentals Summary
| 6L9 fundamental statistics | |
|---|---|
| Market cap | €17.37k |
| Earnings (TTM) | -€104.59m |
| Revenue (TTM) | €100.27m |
0.0x
P/S Ratio0.0x
P/E RatioIs 6L9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6L9 income statement (TTM) | |
|---|---|
| Revenue | US$105.86m |
| Cost of Revenue | US$97.34m |
| Gross Profit | US$8.52m |
| Other Expenses | US$118.94m |
| Earnings | -US$110.41m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 8.05% |
| Net Profit Margin | -104.30% |
| Debt/Equity Ratio | 140.7% |
How did 6L9 perform over the long term?
See historical performance and comparison